Patents by Inventor Mihalis Kariolis

Mihalis Kariolis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION PROTEINS COMPRISING ENZYME REPLACEMENT THERAPY ENZYMES
    Publication number: 20200277584
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Application
    Filed: October 1, 2018
    Publication date: September 3, 2020
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Giuseppe ASTARITA, Mark S. DENNIS, Jennifer A. GETZ, Anastasia HENRY, Mihalis KARIOLIS, Cathal MAHON, Adam P. SILVERMAN, Ankita SRIVASTAVA, Julie ULLMAN, Junhua WANG, Joy Yu ZUCHERO
  • ENGINEERED POLYPEPTIDES
    Publication number: 20200262890
    Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
    Type: Application
    Filed: September 17, 2019
    Publication date: August 20, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
  • ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20200223935
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 16, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Engineered polypeptides
    Patent number: 10457717
    Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 29, 2019
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
  • FUSION PROTEINS COMPRISING ENZYME REPLACEMENT THERAPY ENZYMES
    Publication number: 20190249155
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Application
    Filed: March 15, 2019
    Publication date: August 15, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Anastasia Henry, Mihalis Kariolis, Cathal Mahon, Adam P. Silverman, Ankita Srivastava
  • ENGINEERED POLYPEPTIDES
    Publication number: 20180237496
    Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
    Type: Application
    Filed: March 23, 2018
    Publication date: August 23, 2018
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
  • MODULATION OF AXL RECEPTOR ACTIVITY IN COMBINATION WITH CYTOREDUCTIVE THERAPY
    Publication number: 20180140679
    Abstract: Compositions and methods are provided for treating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6. The treatment may be combined with a cytoreductive therapy.
    Type: Application
    Filed: November 20, 2017
    Publication date: May 24, 2018
    Inventors: Amato J. Giaccia, Jennifer R. Cochran, Yu Miao, Mihalis Kariolis
  • INHIBITION OF AXL/GAS6 SIGNALING IN THE TREATMENT OF LIVER FIBROSIS
    Publication number: 20180094034
    Abstract: Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Inventors: Patrick O'Connor, Raymond Tabibiazar, Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • ANTIFIBROTIC ACTIVITY OF GAS6 INHIBITOR
    Publication number: 20180057898
    Abstract: Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: December 17, 2015
    Publication date: March 1, 2018
    Inventors: Raymond Tabibiazar, Amato J. Giaccia, Mihalis Kariolis, Yu Rebecca Miao
  • MODIFIED AXL PEPTIDES AND THEIR USE IN INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY
    Publication number: 20180030422
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 1, 2018
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Cynthia Fuh, Yu Miao, Susan Hershenson
  • Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
    Patent number: 9879061
    Abstract: Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: January 30, 2018
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Aravive Biologics, Inc.
    Inventors: Patrick O'Connor, Raymond Tabibiazar, Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 9822347
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: November 21, 2017
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Aravive Biologics, Inc.
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao, Susan Hershenson
  • HIGH-AFFINITY BINDING TO GAS6
    Publication number: 20160266136
    Abstract: Compositions and methods are provided for measuring the amount of GAS6 in a sample. Also provided are compositions and methods related to high-affinity CAS6 inhibitor agents that induce a conformational change of GAS6 that stabilizes Helix A of GAS6.
    Type: Application
    Filed: December 12, 2013
    Publication date: September 15, 2016
    Inventors: Jennifer R. Cochran, Amato J. Giaccia, Yu Miao, Mihalis Kariolis, Shiven Kapur, Irimpan I. Mathews
  • Inhibition of AXL Signaling in Anti-Metastatic Therapy
    Publication number: 20160108378
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Application
    Filed: May 14, 2015
    Publication date: April 21, 2016
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 9266947
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: February 23, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Inhibition of AXL Signaling in Primary Tumor Therapy
    Publication number: 20150315552
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 5, 2015
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic Therapy
    Publication number: 20150315553
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 5, 2015
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao, Susan Hershenson
  • Inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 9074192
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: July 7, 2015
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Inhibition of AXL Signaling in Anti-Metastatic Therapy
    Publication number: 20140065143
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Application
    Filed: July 24, 2013
    Publication date: March 6, 2014
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Inhibition of AXL signaling in anti-metastatic therapy
    Patent number: 8618254
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: December 31, 2013
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao